Parkinson's Disease as a Potential Stuck Program Mode of the Candida albicans Biochemical Computer

Dopaminergic Interface Burnout (Speculative Extension)

J. Craddock
Redacted Science Research Initiative
April 2026

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra, producing motor symptoms (tremor, rigidity, bradykinesia) and non-motor symptoms (constipation, depression, cognitive decline, anosmia) that often precede motor onset by decades. The non-motor prodrome, particularly the gastrointestinal symptoms, has led to increasing interest in the gut-brain axis as a contributor to PD pathogenesis. This paper applies the biochemical computer framework (Craddock, 2026a; 2026b) to propose, speculatively, that PD may represent a stuck program mode in which the commensal fungal symbiont Candida albicans drives sustained dopaminergic interface engagement and neurotoxic kynurenine pathway metabolite production, resulting in progressive burnout of substantia nigra neurons. A program refined for Homo Candidus with a likely limited duration, but in this case stuck without an exit due to version conflict. This candidate is explicitly presented as a speculative extension of the framework. The mechanistic chain requires more intermediary steps than the other conditions in this series, and the clustering evidence is the weakest of any candidate. The paper is included to demonstrate the framework's range, to generate testable hypotheses, and to identify the specific evidentiary gaps that would need to be filled to strengthen or reject the proposal.

Keywords: Parkinson's disease, Candida albicans, dopamine, Gpr1, kynurenine, quinolinic acid, brain-gut axis, substantia nigra, neurodegeneration, stuck program mode, speculative, Homo candidus, tryptophan, melatonin, sleep architecture, glymphatic clearance, alpha-synuclein, REM sleep behavior disorder, quinolinic acid, vagus nerve, vagotomy, cannabidiol, lemon balm, rosmarinic acid, acetylcholinesterase, muscarinic receptor, version conflict, NAD+

I. Introduction and Epistemic Status

This paper should be read differently from the others in this series. Type 2 diabetes, anorexia nervosa, irritable bowel syndrome, and obesity each pass three selection gates, documented organism mechanism mapping to central disease pathology, unexplained persistence, and demographic clustering consistent with organism dynamics, with sufficient strength to support confident application of the framework. Parkinson's disease passes two of the three gates with caveats, and the third weakly.

The paper is included for three reasons. First, the gut-brain axis in PD is under active investigation, and the framework offers a specific mechanistic hypothesis within that space that differs from current proposals. Second, the predictions generated are testable and would either strengthen or eliminate the candidate efficiently. Third, the framework's credibility is served by demonstrating where its explanatory power reaches confidently and where it extends speculatively, rather than presenting all applications at uniform confidence. [*Think of it as a stretch goal*]

Where the argument depends on inference rather than documented mechanism, the text says so explicitly.

II. The Mechanism

Dopaminergic Interface

The organism's primary morphogenetic GPCR, Gpr1, responds to clozapine, an antipsychotic that blocks G-protein-coupled dopamine receptors (Midkiff et al., 2011). Clozapine inhibits C. albicans morphogenesis through this pathway, which feeds into the cAMP-PKA signaling cascade governing the organism's tissue engagement decisions. No dedicated dopamine receptor has been identified in C. albicans. The evidence is pharmacological overlap, not confirmed receptor-ligand interaction. What the data shows is that the organism's primary environmental sensing pathway and the host's dopaminergic signaling landscape share sufficient molecular overlap that a drug targeting one affects the other.

Within the framework, this overlap suggests that the organism's management of its own morphogenetic decisions has functional consequences in the host's dopaminergic signaling environment. The organism does not need a dedicated dopamine receptor to affect dopaminergic tone. It needs only to operate in an environment where its metabolites, signaling molecules, and receptor interactions influence the same pathways that dopamine governs.

Kynurenine Pathway and Neurotoxicity

The organism's diversion of tryptophan through the kynurenine pathway (Cheng et al., 2010; Zelante et al., 2013) produces quinolinic acid as a downstream metabolite. Quinolinic acid is a potent NMDA receptor agonist and documented neurotoxin. In the context of AN and IBS (companion papers), the kynurenine diversion serves immune evasion and behavioral modification. In the context of PD, the relevant output is the neurotoxic metabolite itself.

Sustained quinolinic acid production over decades would produce cumulative neurotoxic stress on dopaminergic neurons, which are among the most metabolically vulnerable cell populations in the brain due to their high energy demands, extensive axonal arborization, and reliance on calcium signaling that makes them susceptible to excitotoxicity. The NMDA agonism of quinolinic acid directly engages the excitotoxic pathway implicated in dopaminergic neuronal death.

This is the most speculative mechanistic step in the paper. The gap between documented kynurenine pathway diversion in the gut and quinolinic acid-mediated neurotoxicity in the substantia nigra requires intermediary steps including systemic transport of kynurenine pathway metabolites, blood-brain barrier crossing, and local concentration sufficient to produce neurotoxic effects. Each step is biologically plausible, but none has been demonstrated in the context of C. albicans colonization specifically.

Cannabis Evidence Through the Framework

Clinical evidence for cannabis benefit in PD, while not conclusive by conventional standards, follows a pattern the framework predicts. Over half [*in an election, that's a win*] of

PD patients report clinical benefit from cannabis use, with the strongest improvements in non-motor symptoms: sleep, anxiety, pain, depression, and restless legs (Yenilmez et al., 2026). These are the downstream outputs of the organism's tryptophan diversion and endocannabinoid management described in Section II. THC temporarily overrides the signaling layer the organism manages, providing relief through the same mechanism as exercise-generated anandamide in anorexia nervosa (Craddock, 2026f) and hot showers in CHS (Craddock, 2026b, Section VI): a temporary bypass of organism-managed suppression. Motor symptom response is inconsistent, which the framework also predicts: by the time motor PD is diagnosed, the neurons THC would be relieving are largely gone. The benefit ceiling is set by how much neuronal capacity remains, not by how effectively THC disrupts the organism's interface.

CBD specifically improved REM sleep behavior disorder in PD patients, the hallmark sleep architecture disruption this paper links to organism-driven melatonin depletion via tryptophan diversion. CBD is both a CB1 negative allosteric modulator that disrupts the organism's signaling interface and a documented antifungal (Bahraminia et al., 2024). It hits the organism from two directions simultaneously, which may explain why it addresses the sleep problem more effectively than THC alone.

The dose-response pattern is informative: frequent cannabis users report higher benefit rates (79%) than occasional users (67%) or single-use patients (25%). Sustained disruption of the organism's signaling layer produces more benefit than intermittent disruption. This is consistent with the framework's therapeutic logic across the entire series.

No cannabis study in PD has measured mycobiome state as a variable. The inconsistency in clinical outcomes across studies is what the framework predicts when an unmeasured intervention is applied to an unmeasured variable. The prediction: cannabis response magnitude in PD patients should correlate with organism colonization density, with higher density patients showing greater non-motor symptom relief because the organism's signaling layer is more active and therefore more susceptible to disruption.

The Dual-Mechanism Feedback Loop: Producing the Toxin, Blocking the Cleanup

The organism's tryptophan diversion through the kynurenine pathway produces not one but two convergent mechanisms for progressive neurodegeneration, and they reinforce each other.

The first mechanism is direct neurotoxicity. The kynurenine pathway produces quinolinic acid, a potent NMDA receptor agonist and documented neurotoxin, as described above. Sustained quinolinic acid production over decades applies cumulative excitotoxic stress to the substantia nigra's dopaminergic neurons, the most metabolically vulnerable neuronal population in the brain.

The second mechanism operates through the same metabolic diversion but attacks from the opposite direction. Over 95% of dietary tryptophan is metabolized through the kynurenine pathway; only approximately 5% is converted to serotonin and subsequently to melatonin (Pocivavsek et al., 2017). When the organism increases kynurenine pathway flux for immune evasion purposes, as documented in Cheng et al. (2010) and Zelante et al. (2013), it is simultaneously starving the serotonin-to-melatonin synthesis pathway. Less tryptophan available for serotonin means less serotonin available for melatonin conversion. The result is degraded sleep architecture, a prediction consistent with the sleep disturbances affecting 60-90% of PD patients and the REM sleep behavior disorder that precedes motor diagnosis by 10-20 years.

Sleep is when the glymphatic system, the brain's metabolic waste clearance pathway, operates at peak capacity (Smedley et al., 2022). Glymphatic flow increases significantly during sleep, clearing neurotoxic metabolites including alpha-synuclein aggregates from the interstitial space. When sleep quality degrades, glymphatic clearance degrades with it. The organism is therefore simultaneously producing a neurotoxin during waking hours and impairing the system that would clear it during sleep. The brain accumulates damage it never gets the chance to repair, not because the clearance system is broken but because the organism's tryptophan diversion has degraded the sleep that powers it.

This tryptophan rerouting simultaneously depletes the serotonin/melatonin precursor (~5% of total flux under normal conditions) while disabling IL-17-mediated mucosal defense, with direct consequences for sleep-wake stability and contextual memory (Pocivavsek et al., 2017). Sleep deprivation further amplifies kynurenine flux via IDO/TDO upregulation, elevating neurotoxic quinolinic acid (Bhat et al., 2020). The two pathways compete directly for the finite tryptophan pool, with melatonin providing feedback regulation (Badawy, 2017). Downstream, kynurenine-driven sleep fragmentation impairs glymphatic clearance of metabolic waste, including α-synuclein, linking symbiont metabolism to long-term neural housekeeping (Scott-Massey et al., 2022; Urso et al., 2025).

This is not two independent pathological processes coincidentally co-occurring in PD. It is one metabolic diversion producing a self-reinforcing feedback loop: kynurenine pathway activation generates quinolinic acid while depleting melatonin, degrading the sleep-dependent clearance that would remove the quinolinic acid. Over decades, the loop tightens. Quinolinic acid accumulates. Dopaminergic neurons burn out. The clinical threshold is crossed. The patient receives a diagnosis decades after the process began.

The framework adds the missing upstream variable: what is chronically activating the kynurenine pathway in these patients? The standard literature identifies inflammation as the primary trigger for the enzyme (indoleamine 2,3-dioxygenase, or IDO) that diverts tryptophan into the kynurenine pathway. The framework identifies a specific, measurable source of that chronic immune activation: a resident organism whose immune evasion strategy depends on sustained tryptophan diversion through the kynurenine pathway (Bhat et al.,2020; Badawy, 2017). The organism is not causing PD through a novel mechanism. It is driving the exact mechanism the existing literature has identified, from an upstream position no one is measuring.

Vagal Pathway

The organism possesses a functional muscarinic receptor responsive to acetylcholine (Nile et al., 2019; Rajendran et al., 2015), providing a direct interface with the vagus nerve in the gut. The Braak hypothesis for PD posits that alpha-synuclein pathology originates in the gut and propagates to the brain via the vagus nerve. Vagotomy reduces PD risk in some epidemiological studies. An organism with confirmed vagal nerve interface, residing in the gut, has physical access to the pathway through which PD pathology is hypothesized to spread.

The framework does not claim the organism produces alpha-synuclein or directly initiates the proteinopathy. It proposes that the organism's sustained engagement with the vagal pathway, as part of its gut management program, could create the conditions of chronic neuroinflammation and immune dysregulation along the gut-brain axis that facilitate alpha-synuclein propagation. This is compatible with the Braak hypothesis rather than alternative to it.

III. The Stuck State (Speculative)

The program phase potentially represented by PD is organism modulation of dopaminergic tone as part of cognitive or behavioral management during advanced program stages. Dopamine governs reward, motivation, motor planning, and executive function. An organism managing host behavior, as the framework proposes C. albicans does in the Homo candidus phenotype (Craddock, 2026b), would need to modulate this system. [*Possibly another element of the trinity, THC? If so, this would be testable with existing datasets*]

In a functioning program, dopaminergic modulation would cycle: periods of enhanced dopaminergic engagement alternating with periods of reduced engagement, allowing the neurons serving this interface to recover. The stuck state would be continuous dopaminergic interface engagement without cycling, analogous to a machine running continuously without maintenance intervals.

The age of onset (typically 60+) is consistent with this interpretation. If the organism begins sustained dopaminergic engagement in early adulthood and the interface burns out over decades of continuous operation, the clinical onset of PD in the seventh decade represents approximately 40 years of accumulated neuronal loss reaching the threshold of clinical detectability. The substantia nigra can lose approximately 80% of its dopaminergic neurons before motor symptoms appear. The long prodromal period of PD, with non-motor symptoms decades before motor onset, is consistent with progressive burnout rather than acute insult.

This is an inference, not a demonstrated mechanism. The framework generates it as a prediction. The prediction requires testing. [*I have enough bricks in the wall, but I would love to add this one*]

IV. The Persistence Problem

PD is progressive and irreversible. L-DOPA, the standard treatment, provides the depleted neurotransmitter but loses efficacy as the neurons producing dopamine continue dying. No current therapy halts the progression.

Within the framework, the progression is driven by continued organism activity. The organism does not reduce its dopaminergic interface engagement as neurons die. It continues running the same program regardless of the neuronal population's capacity to sustain it. Each year of continued operation loses more neurons. L-DOPA addresses the neurotransmitter deficit without addressing the driver, which is why it loses efficacy: there are progressively fewer neurons to respond to it.

If the framework is correct, the implication is sobering: by the time PD is diagnosed, decades of neuronal loss have already occurred. Early intervention, potentially decades before clinical onset, would be required to prevent the damage. This is not clinically actionable in the short term, but it generates a testable epidemiological prediction about long-term antifungal exposure and PD risk.

V. Clustering Evidence

This is the weakest gate for PD and the paper acknowledges it directly.

PD is approximately 90% sporadic, with limited familial clustering beyond known genetic risk factors (LRRK2, GBA, SNCA). This contrasts with the strong familial and demographic clustering seen in T2D, AN, and IBS.

The male predominance (approximately 1.5:1) runs opposite to the female predominance in AN and IBS but is consistent with the organism's documented androgen sensitivity. C. albicans converts androstenediol and androstenedione to testosterone de novo. Male mice are significantly more susceptible to systemic C. albicans than female mice, and gonadectomized males match female resistance (Arroyo-Mendoza et al., 2020). If the organism's dopaminergic interface engagement is modulated by androgen levels, the male predominance in PD follows from the organism's enhanced activity in the male hormonal environment.

Pesticide and rural-living associations with PD risk, consistently documented in the epidemiological literature, could connect to the framework through mycobiome disruption. Herbicides affecting gut fungal populations, particularly compounds targeting the shikimate pathway (glyphosate) or acting as synthetic auxin mimics (dicamba), could alter the organism's gut ecology and program dynamics. This connection remains speculative and is developed further in a separate planned paper on environmental substance effects (Craddock, forthcoming). [*Sounds interesting*]

The age-of-onset clustering around 60+ is the most informative demographic feature within the framework. It is consistent with decades of cumulative burnout rather than an acute trigger, distinguishing PD from conditions with earlier onset (AN, IBS) and connecting it to the time course of sustained organism-driven neuronal stress.

VI. Unfreezing: Therapeutic Implications

PD is the hardest candidate to unfreeze in this series, and the paper states this without qualification.

Prevention Versus Treatment

By the time motor PD is diagnosed, approximately 80% of substantia nigra dopaminergic neurons are lost. The framework predicts that prevention, reducing organism-driven dopaminergic stress decades before clinical onset, would be more effective than treatment after diagnosis. This is not immediately clinically actionable, but it generates the testable prediction that long-term antifungal exposure history should inversely correlate with PD incidence.

Dietary Antifungals as Long-Term Risk Reduction

If the framework is correct, populations with traditional diets high in natural antifungal compounds should show lower PD incidence after controlling for known risk factors. Coconut oil (lauric acid), garlic (allicin), cinnamon (cinnamaldehyde), turmeric (curcumin), and lemon balm (rosmarinic acid, consumed as a common herbal tea across Mediterranean, Middle Eastern, and European traditions) all have documented antifungal properties and are dietary staples in several traditional cuisines. Epidemiological analysis of PD incidence versus dietary antifungal intake across populations would test this prediction.

[*A note on lemon balm for the PD reader: there are no clinical reports of drug interactions between lemon balm and levodopa, carbidopa, or any standard PD medication. It is tea. But here is what makes it interesting beyond the antifungal angle. Lemon balm is a documented acetylcholinesterase inhibitor, meaning it increases acetylcholine availability. The* *organism has a confirmed muscarinic receptor that listens to acetylcholine (Nile et al., 2019). So you are drinking a tea that is antifungal, anxiolytic, and simultaneously increasing the signal the organism's own receptor is tuned to detect. Whether that third effect is therapeutic or complicating in PD specifically, nobody knows, because nobody has looked at it through this framework. But it is worth noting that a single cup of herbal tea is hitting three distinct mechanism layers at once. That is not a coincidence. That is a plant whose biochemistry intersects with the organism-host interface at multiple points, which is exactly what the framework predicts any effective traditional remedy would do: hit the organism, hit the symptom, or hit both through independent pathways. The traditional pharmacopoeias that survived long enough to become cultural staples did so because they worked. The framework offers a reason why.*]

Kynurenine Pathway Intervention

If quinolinic acid from organism-driven tryptophan diversion contributes to dopaminergic neurotoxicity, then interventions that reduce kynurenine pathway flux should slow PD progression. This includes both antifungal approaches, reducing the organism population driving the diversion, and direct kynurenine pathway modulators currently under investigation for neurodegenerative diseases. The framework predicts that antifungal intervention should reduce kynurenine pathway metabolite levels in PD patients, a testable biochemical endpoint independent of clinical outcome.

Vagotomy Evidence

Population studies have found that patients who had their vagus nerve surgically severed (a procedure called truncal vagotomy, once common for treating severe ulcers) went on to develop Parkinson's disease at lower rates than the general population. This is consistent with the framework's proposal that the organism's management program operates through the vagus nerve: cut the highway, reduce the traffic. If the organism's gut-based management program drives neuroinflammation along the vagal pathway, severing that pathway would interrupt the mechanism. This is not proposed as a therapeutic intervention but as convergent evidence: the existing surgical data is consistent with an organism-driven process operating through the gut-brain axis.

The vagotomy finding illustrates the framework's central tension. At low colonization density, severing the vagus nerve removes a pathological input and reduces PD risk. At high colonization density in Homo candidus, the system operates under negative pressure. Breaching it does not disconnect a signal. It collapses the architecture. The same intervention that prevents neurodegeneration in one population would be catastrophic in a managed host. Same nerve, same organism, different density, opposite outcome. [*It is more fragile in some ways and stronger in others.*]

VII. Testable Predictions

Prediction P1: PD patients show elevated oral and/or fecal C. albicans colonization density compared to age-matched controls, after controlling for medication effects (particularly noting that L-DOPA and dopamine agonists may themselves affect the organism through the Gpr1 pathway).

Prediction P2: Kynurenine pathway metabolites (specifically quinolinic acid) in PD patients correlate with C. albicans colonization density, consistent with organism-driven tryptophan diversion as a contributor to neurotoxic metabolite production.

Prediction P3: Long-term dietary antifungal intake (population-level epidemiological data on coconut oil, garlic, cinnamon, turmeric consumption) shows an inverse correlation with PD incidence after controlling for known risk factors.

Prediction P4: Antifungal intervention in early-stage PD patients reduces kynurenine pathway metabolite levels (measurable biochemical endpoint) and produces detectable changes in organism density (measurable microbiological endpoint), independent of whether clinical progression is affected in the short term.

Prediction P5: The non-motor prodrome of PD, particularly the gastrointestinal symptoms (constipation, altered gut motility), correlates with measurable mycobiome changes that precede motor symptom onset, consistent with organism-driven gut management dysfunction predating the dopaminergic burnout that produces clinical PD.

VIII. Limitations

This is the weakest candidate in the series and the limitations are substantial.

Gate 1 (mechanism): No dedicated dopamine receptor has been identified in C. albicans. The Gpr1-clozapine interaction demonstrates pharmacological overlap, not confirmed receptor-ligand binding. The mechanistic chain from gut organism to substantia nigra neuronal death requires multiple intermediary steps (systemic kynurenine metabolite transport, blood-brain barrier crossing, local concentration sufficient for neurotoxicity) that are biologically plausible but undemonstrated in this specific context.

Gate 3 (clustering): PD is 90% sporadic with limited familial clustering. The demographic patterns that strongly support the framework in T2D, AN, and IBS are largely absent in PD. The male predominance is consistent with organism androgen sensitivity but could be explained by multiple alternative mechanisms.

The age-of-onset pattern, while consistent with cumulative burnout, is also consistent with numerous other age-related neurodegeneration models. The framework does not provide a unique explanation for this feature.

The preventive implication, that intervention would need to occur decades before clinical onset, makes the framework difficult to test prospectively. Epidemiological approaches using dietary antifungal intake as a natural exposure variable offer the most practical path to initial testing.

This paper is part of a series applying the biochemical computer framework to chronic disease. The companion umbrella paper (Craddock, 2026d) describes the stuck-program model and selection methodology. The foundational framework is described in Craddock (2026a) and Craddock (2026b). [*I might be right, I'm willing to roll the dice and see if we find supporting science*]

References

Arroyo-Mendoza, M., et al. (2020). The effect of gonadal hormones on susceptibility to Candida albicans. Frontiers in Immunology, 11, 570270.

Badawy, A. A. B. (2017). Tryptophan metabolism in depression and other neurological disorders: A review of the role of the kynurenine pathway and the balance between the serotonin and kynurenine pathways. Journal of Psychopharmacology, 31(9), 1127–1138. https://doi.org/10.1177/0269881117699060

Bahraminia, M., Cui, S., Zhang, Z., Semlali, A., Le Roux, É., Giroux, K.-A., Lajoie, C., Béland, F., & Rouabhia, M. (2025). Effect of cannabidiol (CBD), a cannabis plant derivative, against Candida albicans growth and biofilm formation. Canadian Journal of Microbiology, 71(1), 1–12. https://doi.org/10.1139/cjm-2024-0034

Bhat, A., Pires, A. S., Tan, V., Babu, S., & Guillemin, G. J. (2020). Effects of sleep deprivation on the tryptophan metabolism. International Journal of Tryptophan Research, 13, 1178646920970902. https://doi.org/10.1177/1178646920970902 (PMC7686593)

Cheng, S. C., et al. (2010). Candida albicans dampens host defense by downregulating IL-17 production. European Journal of Immunology, 40(6), 1756-1767.

Craddock, J. (2026a). Candida albicans as a Biochemical Computer. Zenodo. https://doi.org/10.5281/zenodo.19337525

Craddock, J. (2026b). The Saline Oscillation Hypothesis: Endocannabinoid-Mediated Fungal-Hominid Coevolution in the East African Rift Valley. Zenodo. https://doi.org/10.5281/zenodo.19369715

Kennedy, D. O., Wake, G., Savelev, S., Tildesley, N. T. J., Perry, E. K., Wesnes, K. A., & Scholey, A. B. (2003). Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. Neuropsychopharmacology, 28(10), 1871–1881. https://doi.org/10.1038/sj.npp.1300230

Midkiff, J., Borochoff-Porte, N., White, D., & Johnson, D. I. (2011). Small molecule inhibitors of the Candida albicans budded-to-hyphal transition act through multiple signaling pathways. PLoS ONE, 6(9), e25395. https://doi.org/10.1371/journal.pone.0025395

Nile, C., Falleni, M., Cirasola, D., et al. (2019). Repurposing pilocarpine hydrochloride for treatment of Candida albicans infections. mSphere, 4(1), e00689-18. https://doi.org/10.1128/mSphere.00689-18

Pocivavsek, A., Baratta, A. M., Mong, J. A., & Viechweg, S. S. (2017). Acute kynurenine challenge disrupts sleep-wake architecture and impairs contextual memory in adult rats. Sleep, 40(11), zsx141. https://doi.org/10.1093/sleep/zsx141

Rajendran, R., Borghi, E., Falleni, M., Perdoni, F., Tosi, D., Lappin, D. F., O'Donnell, L., Greetham, D., Ramage, G., & Nile, C. J. (2015). Acetylcholine protects against Candida albicans infection by inhibiting biofilm formation and promoting hemocyte function in a Galleria mellonella infection model. Eukaryotic Cell, 14(8), 834–844. https://doi.org/10.1128/EC.00067-15

Scott-Massey, A., Boag, M. K., Magnier, A., Bispo, D., Khoo, T. K., & Pountney, D. L. (2022). Glymphatic system dysfunction and sleep disturbance may contribute to the pathogenesis and progression of Parkinson's disease. International Journal of Molecular Sciences, 23(21), 12928. https://doi.org/10.3390/ijms232112928 (PMC9656009)

Urso, D., Gnoni, V., & Chaudhuri, K. R. (2025). The glymphatic system and sleep dysfunction in Parkinson's disease. Sleep Medicine Clinics, 20(3), 379–387. https://doi.org/10.1016/j.jsmc.2025.06.008

Yenilmez, F., Fründt, O., Hidding, U., & Buhmann, C. (2021). Cannabis in Parkinson's disease: The patients' view. Journal of Parkinson's Disease, 11(1), 309–321. https://doi.org/10.3233/JPD-202260

Zelante, T., Iannitti, R. G., Cunha, C., De Luca, A., Giovannini, G., Pieraccini, G., Zecchi, R., D'Angelo, C., Massi-Benedetti, C., Fallarino, F., Carvalho, A., Puccetti, P., & Romani, L. (2013). Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity, 39(2), 372–385. https://doi.org/10.1016/j.immuni.2013.08.003